Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)-- Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference on Tuesday, June 3, 2025, in New York.

About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250527370148/en/

Investors:
Alex Straus
THRUST Strategic Communications
[email protected]

Source: Autobahn Therapeutics

You May Also Be Interested In

• Nebius Group announces pricing of upsized private offering of $5.0 billion of convertible senior notes
• Asahi Kasei Develops Novel Lithium Pre-doping Technology to Raise Energy Density and Lower Cost of Silicon-rich Lithium-ion Batteries
• Amica CEO Ted Shallcross III Named Among Providence Business News’ 40 ‘Driving Forces’ in Rhode Island